AstraZeneca Pharmaceuticals LP, arguing posttrial against a jury finding that two of plaintiffs’ patents were valid, got an opposite finding, erasing a $107.5 million verdict.
At conclusion of a five-day jury trial in May in the U.S. District Court for the District of Delaware, a jury found AstraZeneca infringed on two patents held by Wyeth LLC, a Pfizer subsidiary.